Gamma Delta T cells

Gamma delta (γδ) T cells are a distinct subset of T lymphocytes with the capacity to recognize cellular stress markers independently of classical antigen presentation. This enables them to respond to abnormal cells, such as transformed or infected cells, in a manner that bridges innate and adaptive immunity.

Their unique biology and broad tumor-recognition potential have made them a focus of increasing interest in next-generation immunotherapy research and investigational development.

What are GDTs?

Gamma delta T cells (GDTs) are an uncommon yet impactful group of immune cells, making up just 1–5% of circulating white blood cells. Unlike conventional T cells, GDTs don’t rely on classical antigen presentation to identify threats. Instead, they act as early responders, detecting stress signals on cells that may be cancerous or infected.

This unique mode of action positions them as an exciting frontier in immune-based therapies. Their capacity to spot subtle biological changes has made them an attractive target for next-generation approaches to cancer and infectious disease. In fact, large-scale genomic analyses spanning over 18,000 tumors across 39 cancer types have linked the presence of GDTs in tumors to more favorable patent outcomes.

Importantly, GDTs aren’t one-size-fits-all. They include distinct subtypes, each with specialized traits that may be leveraged for tailored therapeutic strategies. As research evolves, scientists are exploring how to enhance their function through genetic engineering or combine them with other treatments to expand their potential in the clinic.

Innovative Gamma Delta T Cell Therapy by SL BIO

SL BIO is advancing the frontiers of immunotherapy through the application of gamma delta (γδ) T cell technology, licensed from JY Biomedical. This platform leverages the innate immune surveillance properties of γδ T cells to explore precision-driven strategies in cancer immunology.

Developed through years of focused research and manufacturing refinement, the γδ T cell platform is supported by a U.S. FDA Drug Master File filing (DMF #041080), providing a regulatory framework for quality transparency.

In collaboration with Taipei Medical University, JY Biomedical continues to investigate the role of γδ T cells through academia-industry partnerships. Preclinical research to date has demonstrated promising cytotoxic activity by unmodified γδ T cells across a range of tumor types including models of brain and pancreatic.

At SL BIO, we are expanding this foundation through translational research, scientific collaboration, and disciplined development. Our goal is to responsibly advance γδ T cell platforms that contribute to the evolving landscape of immune-based oncology innovation.